DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer

Research output: Contribution to journalComment/debatepeer-review

47 Scopus citations


Defective DNA mismatch repair (MMR) occurs in approximately 15% of sporadic colorectal cancers (CRCs). Multiple retrospective studies have shown that patients with MMR-deficient CRCs have a more favorable stage-adjusted prognosis compared with those who have MMR-proficient tumors. Evidence also indicates that patients with MMR-deficient colon cancers do not benefit from treatment with adjuvant 5-fluorouracil chemotherapy. Furthermore, recent studies, including a pooled analysis, have validated the prognostic and predictive impact of MMR status in patients with stage II and III colon cancer who were treated in adjuvant chemotherapy trials. Given these data, it can be recommended that MMR status be determined and used to inform clinical decision-making for adjuvant chemotherapy in patients with stage II colon cancer.

Original languageEnglish (US)
Pages (from-to)174-177
Number of pages4
JournalNature Reviews Clinical Oncology
Issue number3
StatePublished - Mar 2010

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer'. Together they form a unique fingerprint.

Cite this